# Kazia Therapeutics Limited

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Kazia Therapeutics Limited).

## Overview

Kazia Therapeutics Limited is an Australian oncology-focused drug development company headquartered in Sydney and listed on Nasdaq under KZIA. Its portfolio centers on paxalisib, an investigational brain-penetrant PI3K/Akt/mTOR inhibitor, alongside discovery programs targeting mechanisms of tumor immune evasion and treatment resistance.

## Products & services

• Paxalisib oncology drug development program
• PI3K/Akt/mTOR pathway inhibitor research
• PD-L1 protein degrader platform
• SETDB1 inhibitor platform
• MSETC bicyclic peptide inhibitor

- **Paxalisib** (70%) — Clinical-stage development of a brain-penetrant PI3K/Akt/mTOR pathway inhibitor for cancer indications.
- **PD-L1 Protein Degrader** (15%) — Preclinical platform designed to address tumor immune evasion and resistance to immunotherapy.
- **SETDB1 Inhibitor Platform** (15%) — Discovery platform targeting SETDB1 biology in aggressive, metastatic, and immunotherapy-resistant solid tumors.

- Paxalisib clinical development for multiple cancers
- PI3K/Akt/mTOR pathway inhibitor research
- PD-L1 protein degrader platform
- SETDB1 inhibitor platform
- MSETC bicyclic peptide inhibitor

## Customers

Kazia is a development-stage biotechnology company and has not disclosed commercial product revenue or an established customer base. Its primary external stakeholders are oncology patients, clinical investigators, hospitals, research institutions, regulators, and potential pharmaceutical partners evaluating its investigational programs. Future commercial customers would likely include healthcare providers and oncology treatment networks purchasing approved therapies, while strategic partners could license or co-develop Kazia assets.

- **Clinical trial institutions** (primary) — Hospitals, academic centers, and investigators conduct trials of paxalisib and other candidates.
- **Oncology patients** (primary) — Patients with cancers such as glioblastoma and triple-negative breast cancer are the intended beneficiaries of development programs.
- **Pharmaceutical partners** (secondary) — Potential licensees or co-development partners provide development, commercialization, or financing capabilities.
- **Regulatory and research stakeholders** (secondary) — Regulators and research organizations evaluate clinical evidence, safety, and translational data.

- Cancer patients may receive therapies if programs gain approval
- Oncology hospitals and clinics would use approved treatments
- Clinical investigators conduct studies of Kazia drug candidates
- Pharmaceutical partners may license or co-develop assets
- Regulators assess safety, efficacy, and product approvals

## Geography

Kazia is headquartered in Sydney, Australia, and reports to U.S. investors as a foreign private issuer through Form 20-F and Form 6-K filings. Its clinical and research activities are internationally oriented, with paxalisib development addressing oncology indications relevant to global pharmaceutical markets. No country-level revenue or authoritative geographic revenue split was disclosed in the available reports.

- Headquarters are in Sydney, Australia
- Nasdaq listing provides access to U.S. capital markets
- Clinical development targets internationally relevant cancer markets
- Paxalisib has been evaluated across multiple oncology studies
- No country-level revenue disclosure was available

## Strategy

Kazia’s strategy is centered on advancing paxalisib across selected oncology indications while building a broader pipeline around treatment resistance and tumor immune evasion. The company is also developing earlier-stage PD-L1 degrader and SETDB1 inhibitor programs to reduce reliance on a single clinical asset and create additional partnering opportunities. Progress depends on generating clinical evidence, securing funding, and converting scientific findings into regulatory and commercial value.

- **Advance paxalisib clinical development** (short-term) — Clinical validation is the main route to regulatory approval and future commercial value.
- **Expand the oncology pipeline** (medium-term) — Additional mechanisms can diversify the portfolio beyond the lead asset.
- **Develop strategic and financing relationships** (medium-term) — Partnerships and capital are needed to fund trials and support eventual commercialization.

- Advance paxalisib through oncology clinical development
- Evaluate paxalisib across multiple cancer indications
- Build platforms targeting immunotherapy resistance
- Generate translational evidence for novel mechanisms
- Pursue partnerships and capital to fund development

## Risks

Kazia’s value is concentrated in investigational oncology programs, particularly paxalisib, so unfavorable clinical results, safety findings, or regulatory decisions could materially impair the business. The company also faces biotechnology funding and dilution risk because clinical development requires substantial capital before product revenue. Competitive drug discovery, intellectual-property limitations, licensing obligations, manufacturing requirements, and difficulty translating preclinical findings into patient benefit add further uncertainty.

- **Paxalisib clinical failure** [critical] — The lead asset remains investigational and requires convincing efficacy and safety data across cancer indications.
- **Regulatory approval risk** [high] — Clinical evidence may not satisfy regulators or may lead to additional trials and delays.
- **Capital and dilution risk** [high] — Long oncology development timelines require external financing before meaningful commercial revenue.
- **Pipeline concentration** [high] — Dependence on paxalisib increases sensitivity to setbacks in its clinical or partnering trajectory.
- **Intellectual property and licensing risk** [medium] — Paxalisib was licensed from Genentech, making rights, royalties, obligations, and patent duration relevant to value capture.

- Clinical failure could reduce the value of paxalisib
- Regulatory setbacks may delay or prevent commercialization
- Funding needs can create dilution and financing risk
- Pipeline concentration increases dependence on paxalisib
- Preclinical results may not translate into patient benefit
- Competing oncology therapies may limit market adoption

## Accounting

As a development-stage biotechnology company, Kazia’s reported results are likely driven primarily by research and development spending, collaboration or licensing costs, financing activity, and non-cash share-based or warrant-related charges rather than product revenue. Clinical-trial capitalization, acquired intellectual property, contingent milestones, and impairment assessments can materially affect reported assets and expenses. Investors should also monitor going-concern disclosures, foreign-exchange effects from its Australian base and U.S. listing, and the accounting treatment of equity financings and warrants.

- **Research and development expense** — Reported earnings and operating cash flow
- **Intangible asset impairment** — Non-cash impairment expense and asset carrying values
- **Contingent licensing obligations** — Future expenses, liabilities, and economics of commercialization
- **Warrant and equity financing accounting** — Net income, liabilities, and diluted share count
- **Going-concern assessment** — Financial statement disclosures and financing interpretation

- R&D costs are generally expensed before product commercialization
- Clinical assets may require impairment assessment
- Licensed rights and milestones involve valuation judgments
- Warrants and equity financing can create non-cash charges
- Going-concern assessments reflect funding requirements
- Foreign-exchange movements may affect reported results

---

*Last updated: 2026-09-08T05:51:37.640867+00:00*